HIGHLIGHTS
SUMMARY
CD22∆E12 is associated with aggressive in_vivo growth of human B-ALL cells in mouse xenograft models. The authors set out to test the hypothesis that B-ALL patients with very low levels of CD22E12 ("CD22E12low "), as measured by RNAseq-based CD22E12 mRNA levels, would have a worse prognosis than other B-ALL patients. The expression level of CD22E12 in the B-ALL samples (n=421) was estimated from the mean signal value for the 3 CD22E12 probes, namely HG-U133_PLUS_2:217422_S_AT_7 aligned to chr19:35836590-35836614, HG-U133_PLUS_2:217422_S_AT_6 aligned to chr19:3583656635836590 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.